Автореферат (1154760), страница 5
Текст из файла (страница 5)
90 (96.8%)patients had a history of asthma. The most common EGPA manifestations at diagnosisincluded ENT manifestations, constitutional symptoms and peripheral nervous systeminvolvement (88.2%, 84.9% и 73.1%, respectively). The follow up duration was 587.7patient-years. There were no deaths during follow. The 3- and 5-year relapse-freesurvival rate was 65.4% and 43.1%, respectively. Thirty seven of 93 patients (39.8%)were ANCA-positive. Demographic characteristics were similar in the ANCA-negativeand ANCA-positive patients.
ANCA-positive patients had more frequent mononeuritismultiplex (р=0.01), myalgia (р=0.02), kidney involvement (р=0.16) and higher diseaseactivity (р<0,01), than the ANCA-negative patients. The frequency of vasculitisrelapses was 21.0 per 100 patient-years in the ANCA-positive group versus 19.6 per100 patient-years in the ANCA-negative group (P=0.4). The 3- and 5-year relapse-freesurvival rate were similar in both groups (р=0.26 и р=0.3, respectively).
Vasculitisflares were associated with a modest increase serum C-reactive protein and eosinophilcount. Serum eotaxin-3 and IL-6 levels are not useful to measure activity in relapsingEGPA. Study demonstrated, that relapsing EGPA can treated with rituximab..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
